Kate Haviland Blueprint Medicines Corp (BPMC) insider trading activity

BPMC Quotes by TradingView

Kate Haviland is Chief Executive Officer of Blueprint Medicines Corp. Currently has a direct ownership of 0 shares of BPMC, which is worth approximately $0. The most recent transaction as insider was on Mar 01, 2021, when has been sold 13,062 shares (Common Stock) at a price of $0.0 per share, resulting in proceeds of $0. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 0
100.0% 3M change
100.0% 12M change
Total Value Held $0

Kate Haviland Transaction History

Date Transaction Value Shares Traded Shares Held Form
Mar 01 2021
BUY
Grant, award, or other acquisition
-
13,062 Added 18.94%
55,900 Common Stock
Nov 16 2020
SELL
Open market or private sale
$41,010 $100.27 p/Share
409 Reduced 0.95%
42,838 Common Stock
Nov 16 2020
BUY
Exercise of conversion of derivative security
$14,744 $36.05 p/Share
409 Added 0.94%
43,247 Common Stock
Oct 16 2020
SELL
Open market or private sale
$1,354,068 $101.55 p/Share
13,334 Reduced 23.74%
42,838 Common Stock
Oct 16 2020
BUY
Exercise of conversion of derivative security
$480,691 $36.05 p/Share
13,334 Added 19.18%
56,172 Common Stock

Also insider at

FULC
Fulcrum Therapeutics, Inc. Healthcare
BCAX
Bicara Therapeutics Inc.
Director
KH

Kate Haviland

Chief Executive Officer
Cambridge, MA

Track Institutional and Insider Activities on BPMC

Follow Blueprint Medicines Corp and customize your updates to receive the information that matters most to you.

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells BPMC shares.

Notify only if

Insider Trading

Get notified when an Blueprint Medicines Corp insider buys or sells BPMC shares.

Notify only if

News

Receive news related to Blueprint Medicines Corp

Choose your preferred platform and Sign Up 👇 Telegram Email
Track Activities on BPMC